Arthritis drug reduces COVID-19 deaths in study

Sailors assigned to the hospital ship USNS Mercy (T-AH 19) treat the first patient from Los Angeles medical facilities March 29
(Image credit: U.S. Navy via Getty Images)

The arthritis drug tocilizumab has been shown to reduce deaths among patients hospitalized with severe COVID-19 in a new study.

In the trial, 2,022 hospitalized COVID-19 patients received tocilizumab, while 2,094 patients received usual care; in the former group, 29 percent of patients died within 28 days, while 33 percent of patients died within 28 days in the latter group, BBC News reports. Eighty-two percent of patients were taking a systemic steroid like dexamethasone in the trial.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Brendan Morrow

Brendan worked as a culture writer at The Week from 2018 to 2023, covering the entertainment industry, including film reviews, television recaps, awards season, the box office, major movie franchises and Hollywood gossip. He has written about film and television for outlets including Bloody Disgusting, Showbiz Cheat Sheet, Heavy and The Celebrity Cafe.